全文获取类型
收费全文 | 5371篇 |
免费 | 326篇 |
国内免费 | 73篇 |
专业分类
耳鼻咽喉 | 91篇 |
儿科学 | 70篇 |
妇产科学 | 85篇 |
基础医学 | 542篇 |
口腔科学 | 188篇 |
临床医学 | 510篇 |
内科学 | 1445篇 |
皮肤病学 | 55篇 |
神经病学 | 663篇 |
特种医学 | 273篇 |
外科学 | 899篇 |
综合类 | 5篇 |
预防医学 | 190篇 |
眼科学 | 48篇 |
药学 | 280篇 |
中国医学 | 8篇 |
肿瘤学 | 418篇 |
出版年
2024年 | 10篇 |
2023年 | 94篇 |
2022年 | 82篇 |
2021年 | 291篇 |
2020年 | 216篇 |
2019年 | 231篇 |
2018年 | 241篇 |
2017年 | 155篇 |
2016年 | 220篇 |
2015年 | 232篇 |
2014年 | 276篇 |
2013年 | 352篇 |
2012年 | 498篇 |
2011年 | 469篇 |
2010年 | 259篇 |
2009年 | 224篇 |
2008年 | 289篇 |
2007年 | 313篇 |
2006年 | 252篇 |
2005年 | 234篇 |
2004年 | 228篇 |
2003年 | 197篇 |
2002年 | 143篇 |
2001年 | 27篇 |
2000年 | 11篇 |
1999年 | 20篇 |
1998年 | 36篇 |
1997年 | 28篇 |
1996年 | 21篇 |
1995年 | 17篇 |
1994年 | 15篇 |
1993年 | 14篇 |
1992年 | 16篇 |
1991年 | 11篇 |
1990年 | 10篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1984年 | 2篇 |
1982年 | 4篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1973年 | 3篇 |
1964年 | 1篇 |
1962年 | 1篇 |
1961年 | 1篇 |
1957年 | 1篇 |
1940年 | 1篇 |
1905年 | 1篇 |
排序方式: 共有5770条查询结果,搜索用时 127 毫秒
71.
T M Williams J M Bergman K Brashear M J Breslin C J Dinsmore J H Hutchinson S C MacTough C A Stump D D Wei C B Zartman M J Bogusky J C Culberson C Buser-Doepner J Davide I B Greenberg K A Hamilton K S Koblan N E Kohl D Liu R B Lobell S D Mosser T J O'Neill E Rands M D Schaber J R Huff 《Journal of medicinal chemistry》1999,42(19):3779-3784
72.
Marzena Karcz-Kubicha Katerina Antoniou Anton Terasmaa Davide Quarta Marcello Solinas Zuzana Justinova Antonella Pezzola Rosaria Reggio Christa E Müller Kjell Fuxe Steven R Goldberg Patrizia Popoli Sergi Ferré 《Neuropsychopharmacology》2003,28(7):1281-1291
The involvement of adenosine A(1) and A(2A) receptors in the motor effects of caffeine is still a matter of debate. In the present study, counteraction of the motor-depressant effects of the selective A(1) receptor agonist CPA and the A(2A) receptor agonist CGS 21680 by caffeine, the selective A(1) receptor antagonist CPT, and the A(2A) receptor antagonist MSX-3 was compared. CPT and MSX-3 produced motor activation at the same doses that selectively counteracted motor depression induced by CPA and CGS 21680, respectively. Caffeine also counteracted motor depression induced by CPA and CGS 21680 at doses that produced motor activation. However, caffeine was less effective than CPT at counteracting CPA and even less effective than MSX-3 at counteracting CGS 21680. On the other hand, when administered alone in habituated animals, caffeine produced stronger motor activation than CPT or MSX-3. An additive effect on motor activation was obtained when CPT and MSX-3 were coadministered. Altogether, these results suggest that the motor-activating effects of acutely administered caffeine in rats involve the central blockade of both A(1) and A(2A) receptors. Chronic exposure to caffeine in the drinking water (1.0 mg/ml) resulted in tolerance to the motor effects of an acute administration of caffeine, lack of tolerance to amphetamine, apparent tolerance to MSX-3 (shift to the left of its 'bell-shaped' dose-response curve), and true cross-tolerance to CPT. The present results suggest that development of tolerance to the effects of A(1) receptor blockade might be mostly responsible for the tolerance to the motor-activating effects of caffeine and that the residual motor-activating effects of caffeine in tolerant individuals might be mostly because of A(2A) receptor blockade. 相似文献
73.
Davide Serrano Laura Baglietto Harriet Johansson Frederique Mariette Rosalba Torrisi Marina Onetto Michela Paganuzzi Andrea Decensi 《Clinical cancer research》2005,11(5):2083-2088
PURPOSE: Fenretinide (4-HPR) is a synthetic retinoid that has shown a preventive activity in prostate cancer animal models. EXPERIMENTAL DESIGN: We measured the changes in total and free prostate-specific antigen (PSA) and its association with insulin-like growth factor I (IGF-I) and IGFBP-3 levels after 1 year of treatment in 24 subjects given 4-HPR and 24 control subjects enrolled in a randomized bladder cancer prevention trial. RESULTS: No significant effect of 4-HPR was observed on total and free fraction of PSA levels. The median percentage [95 confidence interval (95% CI)] change for % free PSA and total PSA in the 4-HPR and the control group were, respectively, 7.6 (95% CI, -4.0 to 69.3) versus 5.1 (95% CI, -21.4 to 59.8) and -7.8 (95% CI, -18.2 to 52.5) versus -12.3 (95% CI, -44.6 to 9.6). However, in patients ages <60 years, there was a trend to an increase of total free PSA and % free PSA after treatment with 4-HPR that was different from a trend to a decrease in the control group (P = 0.002 and 0.052, respectively). The interaction between age and treatment was statistically significant on free PSA (P = 0.001). A similar pattern was noted with smoking status (P = 0.011 for the interaction on free PSA). No association was observed between PSA levels and IGF-I or IGFBP-3 levels. CONCLUSIONS: We conclude that 4-HPR has no significant effect on circulating PSA, but it increases significantly free PSA levels in subjects younger than 60 years and in nonsmokers. These effects might support an activity in prostate cancer prevention but further studies are required. 相似文献
74.
Melina Verso Giancarlo Agnelli Sergio Bertoglio Franco C Di Somma Francesco Paoletti Walter Ageno Mario Bazzan Pasquale Parise Roberto Quintavalla Emanuele Naglieri Armando Santoro Davide Imberti Mariella Sorarù Stefano Mosca 《Journal of clinical oncology》2005,23(18):4057-4062
PURPOSE: The extent of venous thromboembolism (VTE) associated with central vein catheters (CVC) in cancer patients remains unclear. The aim of this study was to evaluate the efficacy and safety of the low molecular weight heparin, enoxaparin, in the prevention of VTE. PATIENTS AND METHODS: In a multicenter, double-blind study, consecutive cancer patients scheduled for CVC insertion were randomly assigned to receive either subcutaneous enoxaparin 40 mg once a day or placebo. Treatment was started 2 hours before CVC insertion and continued for 6 weeks. The primary end points of the study were deep vein thrombosis (DVT), confirmed by venography of the CVC limb performed 6 weeks after randomization, or clinically overt pulmonary embolism, confirmed by objective testing during the study drug administration. Patients were assessed for bleeding complications. RESULTS: Three hundred eighty-five patients were randomized, of which 321 (83.4%) underwent venography. A venography was adequate for adjudication in 155 patients in each treatment group. A DVT was observed in 22 patients (14.1%) treated with enoxaparin and in 28 patients (18.0%) treated with placebo, corresponding to a relative risk of 0.78 (95% CI, 0.47 to 1.31). No major bleeding occurred. Five patients (2.6%) in the enoxaparin group and two patients (1.0%) in the placebo group died during the treatment period. CONCLUSION: In this study, no difference in the rate of CVC-related VTE was detected between patients receiving enoxaparin and patients receiving placebo. The dose of enoxaparin used in this study proved to be safe. Clinical trials evaluating higher enoxaparin doses could optimize the efficacy of this agent for this indication. 相似文献
75.
Alessio Nencioni Lucia Wille Giovanna Dal Bello Davide Boy Gabriella Cirmena Sebastian Wesselborg Claus Belka Peter Brossart Franco Patrone Alberto Ballestrero 《Clinical cancer research》2005,11(11):4259-4265
PURPOSE: Bcl-2 overexpression is frequently detected in lymphoid malignancies, being associated with poor prognosis and reduced response to therapy. Here, we evaluated whether Bcl-2 overexpression affects the cytotoxic activity of proteasome inhibitors taken alone or in association with conventional anticancer drugs or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). EXPERIMENTAL DESIGN: Jurkat cells engineered to overexpress Bcl-2 were treated with proteasome inhibitors (MG132, epoxomicin, and bortezomib), anticancer drugs (etoposide and doxorubicin), TRAIL, or combinations of these compounds. Cell death and loss of mitochondrial transmembrane potential were detected by flow cytometry. Cytosolic relocalization of cytochrome c and SMAC/Diablo, caspase cleavage, and Bcl-2 and Mcl-1 levels were determined by immunoblotting. Nuclear factor-kappaB inhibition was done by retroviral transduction with a dominant-negative mutant of IkappaBalpha. RESULTS: Bcl-2 overexpression results in significant inhibition of apoptosis in response to proteasome inhibitors, antiblastics, and TRAIL. Addition of TRAIL to proteasome inhibitors results in a synergistic cytotoxic effect in Bcl-2-overexpressing cells, whereas this result is not reproduced by the combination of proteasome inhibitors with antiblastic drugs. Importantly, proteasome inhibitors plus TRAIL induce mitochondrial dysfunction irrespective of up-regulated Bcl-2. Bcl-2 cleavage to a fragment with putative proapoptotic activity and elimination of antiapoptotic Mcl-1 may both play a role in proteasome inhibitors-TRAIL cooperation. Conversely, nuclear factor-kappaB inhibition by proteasome inhibitors is per se insufficient to explain the observed synergy. CONCLUSIONS: Combined proteasome inhibitors and TRAIL overcome the apoptotic threshold raised by Bcl-2 and may prove useful in the treatment of chemoresistant malignancies with up-regulated Bcl-2. 相似文献
76.
77.
Pharmaceutical Research - Present (i) an infrared (IR)-based Process Analytical Technology (PAT) installed in a lab-scale freeze-dryer and (ii) a micro freeze-dryer (MicroFD®) as effective... 相似文献
78.
Recurrent NAB2–STAT6 gene fusions and oestrogen receptor‐α expression in pulmonary adenofibromas 下载免费PDF全文
Nicola Fusco Elena Guerini‐Rocco Claudia Augello Andrea Terrasi Giulia Ercoli Caterina Fumagalli Davide Vacirca Paola Braidotti Antonina Parafioriti Marta Jaconi Letterio Runza Vijayalakshmi Ananthanarayanan Fabio Pagni Silvano Bosari Massimo Barberis Stefano Ferrero 《Histopathology》2017,70(6):906-917
79.
Charalampia G. Korea Giuliana Balsamo Alfredo Pezzicoli Christina Merakou Simona Tavarini Fabio Bagnoli Davide Serruto Meera Unnikrishnan 《Infection and immunity》2014,82(10):4144-4153
The opportunistic pathogen Staphylococcus aureus is one of the major causes of health care-associated infections. S. aureus is primarily an extracellular pathogen, but it was recently reported to invade and replicate in several host cell types. The ability of S. aureus to persist within cells has been implicated in resistance to antimicrobials and recurrent infections. However, few staphylococcal proteins that mediate intracellular survival have been identified. Here we examine if EsxA and EsxB, substrates of the ESAT-6-like secretion system (Ess), are important during intracellular S. aureus infection. The Esx proteins are required for staphylococcal virulence, but their functions during infection are unclear. While isogenic S. aureus esxA and esxB mutants were not defective for epithelial cell invasion in vitro, a significant increase in early/late apoptosis was observed in esxA mutant-infected cells compared to wild-type-infected cells. Impeding secretion of EsxA by deleting C-terminal residues of the protein also resulted in a significant increase of epithelial cell apoptosis. Furthermore, cells transfected with esxA showed an increased protection from apoptotic cell death. A double mutant lacking both EsxA and EsxB also induced increased apoptosis but, remarkably, was unable to escape from cells as efficiently as the single mutants or the wild type. Thus, using in vitro models of intracellular staphylococcal infection, we demonstrate that EsxA interferes with host cell apoptotic pathways and, together with EsxB, mediates the release of S. aureus from the host cell. 相似文献
80.
Alessandro Squizzato Davide Luciani Andrea Rubboli Leonardo Di Gennaro Raffaele Landolfi Carlo De Luca Fernando Porro Marco Moia Sophie Testa Davide Imberti Guido Bertolini 《Internal and emergency medicine》2013,8(8):695-702
Most cardiopulmonary diseases share at least one symptom with pulmonary embolism (PE). The aim of this study was to identify the most common acute causes of dyspnea, chest pain, fainting or palpitations, which diagnostic procedures were performed and whether clinicians investigate them appropriately. An Italian multicenter collaboration gathered 17,497 Emergency Department (ED) records of patients admitted from January 2007 to June 2007 in six hospitals. A block random sampling procedure was applied to select 800 hospitalised patients. Results of the overall 17,497 patients were obtained by weighting sampled cases according to the probability of the randomisation block variables in the whole population. The case-mix of enrolled patients was assessed in terms of cardiopulmonary symptoms, and the prevalence of acute disorders. The actual performance of procedures was compared with a measure of their accuracy as expected in the most common clinical presentations. PE occurred in less than 4% of patients with cardiopulmonary symptoms. Acute heart failure, pneumonia and chronic obstructive pulmonary disease exacerbation were the most likely diagnoses in patients with dyspnea. Acute myocardial infarction was present in roughly 10% of patients with chest pain. Atrial fibrillation was the prevalent diagnosis in patients with palpitations. Echocardiography, computed tomographic pulmonary angiography, perfusion lung scan, D-dimer test and B-type natriuretic peptide were performed less than expected from their accuracy. Diagnostic strategies, starting from non-specific symptoms and coping with the eventuality of PE, are likely to benefit from an increased awareness of the examination’s accuracy in discriminating among several competing hypotheses, rather than in testing the single PE suspicion. 相似文献